FGFR1 is a widely expressed member of the FGFR family both in mouse and in human blood and lymphatic endothelial cells (LECs; Extended Data Fig. 1a, b) . Knockdown of FGFR1 resulted in upregulation of FGFR3 expression, while FGFR3 downregulation had no effect on other FGFR expression (Extended Data Fig. 1c, d 
Here we identify FGF receptor (FGFR) signalling as a critical regulator of vascular development. This is achieved by FGF-dependent control of c-MYC (MYC) expression that, in turn, regulates expression of the glycolytic enzyme hexokinase 2 (HK2).
A decrease in HK2 levels in the absence of FGF signalling inputs results in decreased glycolysis, leading to impaired endothelial cell proliferation and migration. Pan-endothelial-and lymphaticspecific Hk2 knockouts phenocopy blood and/or lymphatic vascular defects seen in Fgfr1/Fgfr3 double mutant mice, while HK2 overexpression partly rescues the defects caused by suppression of FGF signalling. Thus, FGF-dependent regulation of endothelial glycolysis is a pivotal process in developmental and adult vascular growth and development.
FGFR1 is a widely expressed member of the FGFR family both in mouse and in human blood and lymphatic endothelial cells (LECs; Extended Data Fig. 1a, b) . Knockdown of FGFR1 resulted in upregulation of FGFR3 expression, while FGFR3 downregulation had no effect on other FGFR expression (Extended Data Fig. 1c, d (BAC) ;Fgfr3 −/− ) specific knockouts. The excision efficiency of both Cre drivers was assessed by crossing them with the mTmG reporter mice. Cre activation at embryonic day (E)12.5 and E13.5 resulted in a high degree of recombination in the skin lymphatic vessels at E15.5 with both Cre deleters (Extended Data Fig. 1e, f) .
The effect of these deletions on lymphatic development was examined using embryonic skin as a readout 7 . LECs start to invade anterior dorsal skin at E12.5 and migrate towards the dorsal midline. By E15.5-E16, lymphatic vessels from both sides fuse at the dorsal midline forming a primary lymphatic network (Fig. 1a, b) . Whole-mount staining of the embryonic mouse skin with anti-VEGFR3 and PECAM1 antibodies in single knockout Fgfr1 iΔLEC (BAC) or Fgfr3 −/− mice revealed no abnormalities in lymphatic front migration (Extended Data Fig. 1g-j) . Pan-endothelial Fgfr1 deletion on the Fgfr3 −/− background at E10.5 resulted in significant oedema, the appearance of blood-filled lymphatics and reduced dermal lymphatic development (Extended Data Fig. 2a-e) . When the deletion was activated a day later (E11.5), reduced migration and branching of lymphatics were still evident (Extended Data Fig. 2f-i) . Analysis of LEC-specific Fgfr1/Fgfr3 double knockout mice (tamoxifen treatment at E12.5 and E13.5) confirmed these findings, showing decreased LEC front migration, branching and fewer LECs in the skin (Fig. 1c-g ). There was no appreciable difference in the size of the skin lymphatic vessels (Fig. 1f, h ). To explore FGFR inhibition in suppression of pathological lymphangiogenesis, mice with orthotopic Panc02 tumours were orally treated with the SSR128129E (SSR) inhibitor 8 . There was a significant reduction of lymphangiogenesis in the peri-tumoural area in the inhibitor-treated mice compared with vehicle controls (Extended Data Fig. 2j, k) , indicating a potential therapeutic value of FGFR inhibitors as anti-lymphangiogenic agents.
We next examined whether FGF signalling plays a similar role in the blood vessel development. Analysis of Fgfr1 iΔEC ;Fgfr3 −/− mice after Cre activation at E10.5 showed a significant reduction in vessel branching and coverage in the skin at E15.5 (Extended Data Fig. 3a-d) . Examination of the arterial vasculature, revealed by Connexin 40 (Cx40) staining, also showed a reduction in branching (Extended Data Fig. 3f, g ) but no differences in capillary or arterial diameter (Extended Data Fig. 3e, h ).
The involvement of FGF signalling in blood vascular development was further confirmed by examining retinal vasculature in Fgfr1 iΔEC ;Fgfr3 −/− mice after Cre activation at postnatal day (P)0 (Extended Data Fig. 4a ). There was a significant impairment of vascular growth and branching (Extended Data Fig. 4b, c) , and marked reduction in the number of tip cells (Extended Data Fig. 4d , e) and the extent of proliferation (Extended Data Fig. 4f, g ). There was no obvious difference between ;Fgfr3 −/− in vascular density and branching (Extended Data Fig. 4h-k) . Knockdown of FGFR1 in human dermal lymphatic endothelial cells (HDLECs) significantly reduced cell proliferation and migration, while FGFR3 downregulation had no effect (Extended Data Fig. 5a-c) . Effects of a double FGFR1/FGFR3 knockdown were like those of FGFR1 knockdown (Extended Data Fig. 5a-c) .
To establish the molecular basis of FGF-dependent regulation of vascular development, we performed RNA sequencing (RNA-seq) analysis of LECs after stimulation with FGF2 or FGFR1 knockdown. Gene Ontology analysis showed the expected statistical enrichment of molecular pathways related to cell proliferation and migration (Fig. 2a) . Surprisingly, there was also enrichment among cellular metabolism processes and, especially, glucose metabolism pathways. To assess this aspect of FGF biology, we first examined contributions of major metabolic pathways to LEC energy generation. Flux analysis demonstrated that glycolysis was the most active process in LECs (Extended Data Fig. 6a ), contributing to > 70% of the total ATP generation. HDLEC treatment with FGF2 doubled their glycolytic flux (Fig. 2b) and significantly increased glucose uptake (Extended Data  Fig. 6b ). Conversely, knockdown of FGFR1 reduced the flux rate (Fig. 2b) . Steady-state levels of various glycolytic metabolites and lactate were all increased by FGF2 stimulation and decreased after FGFR1 knockdown (Fig. 2c, d ). FGF signalling activation increased, while FGFR1 downregulation reduced, ATP production in HDLECs (Fig. 2e, f) , consistent with the major contribution of glycolysis to energy generation.
To define the regulatory step involved in FGF-dependent control of LEC glycolysis, we analysed the expression of rate-limiting glycolytic . Data represent mean ± s.e.m., * P < 0.05, * * P < 0.01, NS is non-significant, calculated by unpaired t-test (d, e, h) and unpaired t-test with Welch's correction (g). Protein/β-actin (normalized) c, d, Mass spectrometry measurement of glycolytic intermediates and lactate in control and FGF2-and FGFR1 siRNA-treated HDLECs (n = 6 wells of samples for each condition, representative of two or three independent experiments). G-6-P, glucose-6-phosphate; F-6-P, fructose-6-phosphate; F-1,6-BP, fructose-1,6-bisphosphate; DHAP, dihydroxyacetone phosphate; 3-PG, 3-phosphoglycerate; 2-PG, 2-phosphoglycerate; PEP, phosphoenolpyruvate. e, f, Mass spectrometry measurement of ATP generation (n = 6 wells of samples for each condition, representative of two independent experiments). g, h, Western blot analysis (g) and densitometric quantification (h) of glycolytic enzyme expression in control or FGF2-treated HDLECs (n = 6 experiments). i, j, Immunoblot analysis (i) and densitometric quantification (j) of glycolytic enzyme expression in HDLECs treated with control siRNA or FGFR1 siRNA (n = 3 independent experiments). k, qPCR analysis of Hk1 and Hk2 expression in dermal LECs isolated from E15.5 Fgfr1 iΔLEC(BAC) ;Fgfr3 −/− and control embryos with tamoxifen injection at E12.5 and E13.5 (n = 2 litters including four control and two Fgfr1 iΔLEC(BAC) ;Fgfr3 −/− embryos). Data represent mean ± s.e.m., * P < 0.05, * * P < 0.01, * * * P < 0.001, calculated by unpaired t-test (b-f, h, j, k). For gel source data, see Supplementary Fig. 1 .
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enzymes, including hexokinase (HK1 and HK2), phosphofructokinase (PFKP) and pyruvate kinase (PKM2). We also assessed 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3), which regulates blood vessel sprouting 9 . HDLEC stimulation with FGF2 induced a robust increase in HK2 expression, with minimal expression changes of other enzymes (Fig. 2g, h ), while FGFR1 knockdown led to a significant reduction in HK2 (Fig. 2i, j) . Examination of skin LECs isolated from E15.5 Fgfr1 iΔLEC (BAC) ;Fgfr3 −/− embryos confirmed the reduction in Hk2 expression (Fig. 2k) . The importance of HK2 was supported by analysis of RNA-seq data: it was the only glucose metabolic gene among the top 20 transcripts (ranked by fold change) induced by FGF2 and downregulated by FGFR1 knockdown (Extended Data Fig. 6c ).
HK2 knockdown significantly reduced, while adenoviral-mediated HK2 overexpression increased, the glycolytic flux (Extended Data Fig. 6d-f ). Since the knockout of Fgfr1/Fgfr3 in the endothelium also reduced angiogenesis, we examined whether FGF signalling regulates glycolysis and enzyme expression in blood endothelial cells (BECs). As in LECs, treatment of human umbilical vein endothelial cells (HUVECs) with FGF2 enhanced glycolysis and selectively induced HK2 expression (Extended Data Fig. 6g-i . We tested whether any of them also influences glycolysis in HDLECs. While all were effective in increasing cell proliferation, only VEGFC stimulation increased glycolytic flux, albeit to a lesser extent than FGF2 (Extended Data Fig. 6j ). Consistent with these findings, only VEGFC increased HK2 expression without affecting other enzymes (Extended Data Fig. 6k ).
FGF2 stimulation of HDLEC proliferation and migration was significantly reduced by HK2 knockdown (Extended Data Fig. 7a, b) , while FGFR1 knockdown-induced decrease in HDLEC proliferation and migration was rescued by adenoviral HK2 expression (Extended Data Fig. 7c, d ). FGF2-induced LEC sprouting was almost completely blocked by HK2 knockdown (Extended Data Fig. 7e ). FGFR1 knockdown in HDLECs also fully blocked FGF2-induced sprouting, while transduction of HK2 into HDLECs after FGFR1 knockdown partly restored sprouting (Extended Data Fig. 7f) .
We next generated a mouse line with an endothelial-specific deletion of Hk2 To confirm that these defects in lymphatic development were not secondary to any effects of Hk2 deletion in the blood endothelium, we crossed Hk2 flox/flox mice with Prox1-CreER
T2(BAC)
. Immunostaining with anti-VEGFR3 antibody demonstrated a significant reduction in the skin lymphatic vessel development and branching at E15.5 after E12.5 Cre activation ( Fig. 3a-c) .
To examine the role played by Hk2 in adult lymphangiogenesis, FGF2-containing pellets were implanted into corneas of ) and control mice (Fig. 3d) . The Cre recombinase, which was activated at the adult stage to bypass the early lymphatic defects caused by Hk2 knockout, was highly efficient in driving recombination in cornea lymphatics (Fig. 3e) . While adult mice corneas are devoid of both lymphatic and blood vasculature 13 , FGF2 pellet implantation led to robust stimulation of lymphangiogenesis in control mice that was significantly reduced in Hk2 iΔLEC(KI) mice (Fig. 3f, g ). Similar to its role in the lymphatic development, pan-endothelial Hk2 deletion at early developmental stage (E10.5) significantly reduced angiogenesis (Extended Data Data  Fig. 10a, b) . Moreover, knockdown of MYC decreased, while its overexpression increased, HK2 mRNA levels (Extended Data Fig. 10c, d ). MYC knockdown also reduced glycolysis (Extended Data Fig. 10e, f) , iΔLEC(KI) + buffer; n = 11 corneas for control + FGF2; n = 14 corneas for Hk2 iΔLEC(KI) + FGF2). Data represent mean ± s.e.m., * P < 0.05, * * P < 0.01, * * * P < 0.001, calculated by unpaired t-test (b, c) and one-way analysis of variance (ANOVA) plus Sidak's multiple comparisons test (g).
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while MYC overexpression increased glycolytic activity (Extended Data Fig. 10g ).
FGF2 treatment of HDLECs increased MYC protein expression (Fig. 4a) , while FGFR1 knockdown reduced it (Fig. 4b) . Furthermore, ChIP-quantitative PCR (ChIP-qPCR) showed that the amount of MYC binding to the HK2 E-boxes was increased by FGF2 treatment and reduced by FGFR1 knockdown (Fig. 4c) . MYC knockdown selectively reduced HK2 expression and prevented FGF2-induced increase in HK2 levels (Fig. 4d) . Finally, the decrease in HK2 expression after FGFR1 knockdown was completely rescued by overexpression of MYC (Fig. 4e) .
Myc is highly enriched in embryonic dermal LECs (Extended Data  Fig. 10h) . Examination of the lymphatic vasculature in the anterior dorsal skin at E15.5 in Cdh5-CreER T2 ;Myc flox/flox (Myc iΔEC ) mice after Cre activation at E11.5 showed, similarly to Fgfr1/Fgfr3 and Hk2 knockout mice, the presence of oedema (Fig. 4f ) and a reduction in lymphatic vessel growth (Fig. 4g, h ). LEC-specific Myc deletion using Prox1-CreER T2(BAC) confirmed these findings (Extended Data Fig. 10i-k) . In agreement with the study demonstrating Myc involvement in blood vasculature development 15 , MYC knockdown in HUVECs reduced HK2 mRNA and protein expression (Extended Data Fig. 10l-n) , while its overexpression increased HK2 levels (Extended Data Fig. 10o) . Consistently, BECs isolated from Myc iΔEC embryos showed reduced expression of Hk2 but not Hk1 (Extended Data  Fig. 10p ). FGF2 treatment of HUVECs increased MYC expression (Extended Data Fig. 10q, r) . Finally, FGF regulation of MYC was confirmed by the reduction of Myc expression in retinal vasculature of P5 Fgfr1 iΔEC ;Fgfr3 −/− mice (Extended Data Fig. 10 s, t) . Collectively, these results suggest that FGF-dependent regulation of MYC expression underlies control of HK2 levels in LECs and BECs.
These data indicate that FGF signalling plays a pivotal role in both blood and lymphatic vascular development and it is also required for lymphangiogenesis in tumours. At the molecular level, FGFs control glycolysis through an MYC-dependent regulation of HK2 expression. FGF stimulation increased HK2 levels leading to induction of glycolysis and increased production of glycolytic metabolites, while its suppression had the opposite effect. MYC mediates FGF2 effects on HK2 expression by directly binding to HK2 regulatory elements and controlling its transcription. Pan-endothelial and LEC-specific knockout of Myc induces a phenotype closely resembling those seen in 22 (C57BL/6 background) were bred with different Cre lines to assess the recombination efficiency in lymphatics. All mouse protocols and experimental procedures were approved by the relevant Institutional Animal Care and Use Committee. Cell culture and treatment. HDLECs (HMVEC-dLyNeo-Der Lym Endo EGM-2MV) and pooled HUVECs were purchased from Lonza and cultured in EBM2 basal medium with EGM-2 MV BulletKit. Both cell types tested negative for mycoplasma in Lonza. Culture medium was changed every other day. Tissue culture plates were coated with 0.1% gelatin (Sigma) for 30 min at 37 °C and washed with Dulbecco's Phosphate-Buffered Saline (Life Technologies) before cell plating. For siRNA-mediated gene knockdown, FGFR1 siRNA (ON-TARGETplus human FGFR1 siRNA, Dharmacon; SMARTpool siRNAs with four target sequences: GCCACACUCUGCACCGCUA, CCACAGAAUUGGAGGCUAC, CAAAUGCCCUUCCAGUGGG, GAAAUUGCAUGCAGUGCCG), FGFR3 siRNA (Hs_FGFR3_6, Qiagen; target sequence: CCGATGTTATTAGATGTTACA), HK2 siRNA (s6562 human HK2 siRNA, Life Technologies; sense sequence: CAGAGGUUCGAGAAAAUGAtt), MYC siRNA (ON-TARGETplus human MYC siRNA, Dharmacon; SMARTpool siRNAs with four target sequences: ACGGAACUCUUGUGCGUAA, GAACACACAACGUCUUGGA, AACGUUAGCUUCACCAACA, CGAUGUUGUUUCUGUGGAA) or AllStar negative control siRNA (Qiagen) was transfected by Lipofectamine RNAimax reagent (Life Technologies). Human FGF2 was ordered from Peprotech. Human VEGFC, VEGFD, IGF1, IGF2 and PDGFBB were purchased from Peprotech. To assay the effect of FGFR1 knockdown on glycolytic enzyme expression, HDLECs, transfected with control or FGFR1 siRNA three days in advance, were re-plated and collected for protein analysis approximately 24 h later when the cell confluency reached ~ 80%. To examine the influence of growth factor treatment on glycolytic enzymes, freshly plated HDLECs were starved overnight with EBM2 plus 0.1% FBS and then stimulated with FGF2 (100 ng ml −1 or 200 ng ml
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), VEGFC (100 ng ml RNA-seq experimental design and sample preparation. HDLECs treated with or without FGF2 for 14 h were lysed for RNA extraction and were eventually used to generate a list of differentially expressed genes between FGF2 and control, named the 'gain-of-FGF signaling' dataset. Similarly, HDLECs treated with FGFR1 siRNA or negative control siRNA for 3 days were lysed for RNA extraction and were finally used to generate a list of differentially expressed genes between FGFR1 siRNA and negative control siRNA, the so-called 'loss-of-FGF signaling' dataset. For each treatment, nine replicates prepared from three independent experiments were analysed. RNA isolation was performed using an RNeasy Mini Kit (Qiagen). RNA-seq. Extracted total RNA was quantitated by NanoDrop and RNA integrity number value was measured with an Agilent Bioanalyzer. One microgram of qualified RNA (RNA integrity number > 8.0) was used as input for library construction following the Illumina TruSeq RNA Sample Preparation protocol. RNA libraries were sequenced on an Illumina HiSeqX platform, paired-end 2 × 150 base pairs. The average data yield for each sample was 20 million paired-end reads with percentage of Q30 bases > 90. RNA-seq data analysis. RNA-seq reads from each sample were aligned to human genome (build 38) using short reads aligner STAR (version 2.5.1b) 23 . Gene expression quantification was then performed using RSEM 24 with GENCODE annotation (release 24: http://www.gencodegenes.org). Differential analysis was performed using edgeR 25 to identify genes with significant expression changes between groups. Genes observed to change significantly (false discovery rate < 1 × 10 −2 ) in their expression in both the 'gain-of-FGF signaling' dataset and the 'loss-of-FGF signaling' dataset were first identified (1,999 transcripts). If a gene were truly regulated by FGF signalling, it should have shown opposite changing direction between the 'gain-of-FGF signaling' and 'loss-of-FGF signaling' datasets. Therefore, next-step analysis was focused on the 929 transcripts whose expression was upregulated by FGF2 treatment but decreased after FGFR1 knockdown, and the 828 transcripts whose expression was reduced by FGF2 stimulation but increased after FGFR1 knockdown. Those 1,757 transcripts were used for functional enrichment analysis by running GOseq, an algorithm controlling gene length bias in next-generation sequence data 26 . nGOseq, a modified version of the nEASE algorithm 27, 28 which also controls for gene length bias, was used to assess functional enrichment of nested GOseq terms. In brief, each enriched upper-level GOseq term was used for nested GOseq (nGOseq) analysis to identify statistically enriched nested GO terms driving upper-level functional enrichment of non-specific GOseq terms. For generating data in Extended Data Fig. 6c , the top 50 transcripts that were increased by FGF2 treatment (ranked by fold change) and the top 50 transcripts that were reduced after FGFR1 knockdown (ranked by fold change), among those 1,999 transcripts mentioned above, were first identified. Comparing the two lists of top hits resulted in an overlap containing 24 protein-coding genes. Those 24 genes were further ranked by the sum of their absolute log 2 (fold changes) in FGF2 treatment and FGFR1 knockdown conditions. After this ranking, the top 20 genes were shown in Extended Data Fig. 6c . Measurement of glycolysis, glucose oxidation, glutamine oxidation, fatty-acid oxidation and glucose uptake. Glycolysis was measured as previously described 9 . In brief, subconfluent HDLECs cultured in 12-well plates were incubated with 1 ml per well EBM2 medium (containing appropriate amounts of serum and supplement) with 80 μ Ci mmol −1 H]glucose (Perkin Elmer) for 2-3 h. Then 0.8 ml per well medium was transferred into glass vials with hanging wells and filter papers soaked with H 2 O. After incubation in a cell culture incubator for at least two days to reach saturation, filter papers were taken out and the amount of evaporated 3 H 2 O was measured in a scintillation counter. Glucose oxidation, glutamine oxidation and fatty-acid oxidation were measured essentially as reported 9 . For measurement of glucose uptake, HDLECs were incubated with 2-[1-
, Perkin Elmer) for 10 min before PBS washing (at least three times to remove all radioactive medium) and then lysed with 500 μ l 0.1 N NaOH. Four hundred microlitres of NaOH cell lysate for each sample was transferred to scintillation vials containing scintillation liquid and measured. Mass spectrometry analysis of metabolites. HDLECs were quenched by a rapid wash with ice-cold PBS and then collected in 150 μ l of an ice-cold solution containing 20% methanol, 0.1% formic acid, 1 mM phenylalanine, 3 mM NaF and 100 μ M EDTA. [ 2 H 4 ]taurine (10 μ M, CDN Isotopes) was used as a loading control. All the samples were lyophilized and resuspended in 50 μ l of water before the liquid chromatography-tandem mass spectrometry analysis. Samples were injected onto a Cogent Diamond Hydride column (2.2 μ m particle size, 2.1 mm × 10 cm) at a flow rate of 0.5 ml min −1 . Glycolytic intermediates were eluted isocratically with a 95% aqueous/5% organic solvent mixture. The aqueous solution contained 15 mM ammonium formate. The organic solution contained 60% acetonitrile, 35% isopropyl alcohol and 15 mM ammonium formate. Samples were ionized by electrospray into an ABSCIEX 5500 QTRAP equipped with a SelexION for differential mobility separation and acquired using multiple reaction monitoring in negative mode, as described previously 29 . Differential mobility separation-based separation of fructose-6-phosphate from glucose-6-phosphate, as well as the separation of ATP, ADP and AMP nucleotides, was achieved using no modifier. Isopropyl alcohol was used as modifier for the differential mobility separation-based separation of the remaining glycolytic intermediates. Retention times were confirmed with known standards and peaks integrated using Multiquant (ABSCIEX) using the following multiple reaction monitoring transition pairs (Q 1 /Q 3 ): 506/159 for ATP, 426/79 for ADP, 346/79 for AMP, 259/97 for glucose-6-phosphate, 259/97 for fructose-6-phosphate, 339/97 for fructose-1,6-bisphosphate, 169/97 for dihydroxyacetone phosphate (DHAP), 185/79 for 3-phosphoglycerate (3PG), 185/79 for 2-phosphoglycerate (2PG), 167/79 for phosphoenolpyruvate (PEP), 89/89 for lactate and 124/80 for endogenous taurine. Endogenous taurine was used as internal control for cell density as previously described 30 . Seahorse assays. Metabolic analyses in HDLECs were performed with a Seahorse XFe96 analyser (Agilent Seahorse) according to the manufacturer's recommendations. In brief, siRNA-transfected or adenovirus-transduced HDLECs (40,000 cells per well of a 96-well plate) were seeded on fibronectin-coated XFe96 microplates. After 2 h, cell culture medium was changed to a non-buffered assay medium and cells were maintained in a non-CO 2 incubator for 1 h. A Glycolysis Stress Test kit (Agilent Seahorse) was used to monitor the extracellular acidification rate under various conditions. Three baseline recordings were made, followed by sequential injection of glucose (10 mM), the mitochondrial/ATP synthase inhibitor oligomycin (3 μ M), and the glycolysis inhibitor 2-deoxy-d-glucose (2-DG; 100 mM). qPCR analysis. RNA was extracted from cells using the RNeasy Mini Kit or the RNeasy Plus Mini Kit (Qiagen) according to the manufacturer's instructions. cDNA synthesis was performed using the M-MLV reverse transcriptase (Invitrogen) or the LETTER RESEARCH iScript cDNA synthesis kit (Bio-Rad). qPCR was performed either with TaqMan Gene Expression Master Mix (Thermo Fisher Scientific) and TaqMan probes (Thermo Fisher Scientific), or with iQ SYBR Green Supermix (Bio-Rad). For the TaqMan method, the following assays were used: human ACTB Hs99999903_ m1; human MYC Hs00153408_m1; human HK2 Hs00606086_m1; mouse Actb Mm02619580_g1; mouse Hk1 Mm00439344_m1; mouse Hk2 Mm00443385_m1. For SYBR method, qPCR primers for human FGFR1-FGFR4, human GAPDH, human β -actin, mouse Fgfr1-Fgfr4, mouse Hk1 and mouse β -actin were ordered from Qiagen. Mouse Hk2 qPCR primers both purchased from Qiagen and designed in-house were used to generate data for Fig. 2k . The sequences of in-house designed qPCR primers are (5′ to 3′ ): Mouse Hk2 (CGGTACACTCAATGACAT CCGA; TTCACCAGGATGAGTCTGACC) and human RPLP0 (TCTGCATTCT CGCTTCCTGG; CAGGACTCGTTTGTACCCGT). ChIP-qPCR. ChIP assays were performed using SimpleChIP Plus Enzymatic Chromatin IP Kit (Cell Signaling) according to the manufacturer's protocol with some minor modifications. Cells cultured on 20-cm dishes were fixed for 10 min by adding 37% formaldehyde solution to the culture medium to a final concentration of 1%. Fixation was quenched with glycine for 5 min at room temperature. Cells were washed twice with ice-cold PBS, scraped into 2 ml PBS and centrifuged at 5,000 r.p.m. for 10 min. The cell pellets from two 20-cm dishes were combined and lysed in 1 ml lysis buffer. The lysate was then centrifuged at 5,000 r.p.m. for 5 min at 4 °C and the pellet was resuspended in 100 μ l nuclease digestion buffer. The DNA was digested with 0.5 μ l of micrococcal nuclease for 20 min at 37 °C to a length of approximately 150-900 base pairs (checked by agarose gel electrophoresis). Lysates were centrifuged and the pellet was resuspended in 500 μ l ChIP buffer and sonicated for 3 × 30 s at power level 2 and 40% constancy. The solution was centrifuged at 10,000 r.p.m. for 10 min, and the supernatant was collected, which was the cross-linked chromatin. For ChIP, 150 μ l of cross-linked chromatin was used for each immunoprecipitation and mixed with rabbit anti-MYC antibody (Abcam, 1:50) or same amount of rabbit IgG control at 4 °C overnight. Two per cent of cross-linked chromatin was saved as input control for later qPCR reaction. Thirty microlitres of Protein G magnetic bead slurry was added to each immunoprecipitation reaction and incubated for 2 h at 4 °C with rotation. The magnetic beads were washed three times with ChIP low salt buffer and once with ChIP high salt buffer. The bound chromatin on the beads was released in ChIP elution buffer by heating at 65 °C for 30 min with vortex at 1,200 r.p.m. The chromatin was then digested with Protease K and purified using a spin column. The DNA was eventually eluted in 50 μ l DNA elution buffer. The amount of precipitated DNA from each sample was quantified by qPCR using primers flanking the MYC binding element in the HK2 gene. The reading was normalized to that of DNA purified from the previously saved cross-linked chromatin (2% input). The reading by DNA from immunoprecipitation using MYC antibody against that from IgG immunoprecipitation indicated the antibody efficiency for ChIP assay. The qPCR primers (flanking the E-boxes) for detecting the MYC binding element 14 were (5′ to 3′ ) GCCCCGCAGGTAGTCAGG and AGCCACGATTCTCTCCACG. xCELLigence real-time cell analysis (RTCA). HDLEC proliferation was measured by using an xCELLigence RTCA instrument (Roche Dignostics) and E-plate 16 (a modified 16-well plate, Roche Dignostics). The E-plate 16 was coated with 0.1% gelatin, loaded with 100 μ l cell-free medium and left in a tissue culture hood for 30 min to reach equilibrium. The E-plate 16 was placed into the RTCA instrument to measure the background impedance. Thereafter, 100 μ l cell suspensions with fewer than 8,000 cells were added into each well of the E-plate 16, which was then placed in a tissue culture incubator for 30 min to allow cells to settle down before being measured by the RTCA device. The impedance value of E-plate 16 was automatically monitored every 15 min with three or four replicates for each treatment. For experiments requiring measurement of the effect of FGF2 on cell proliferation, HDLECs were resuspended in EBM2 plus 3% FBS before being plated into E-plate 16. Then, 10-12 h after RTCA measurement, the monitor program was paused and E-plate 16 was taken out from the device to add 2 μ l FGF2 or vehicle to each well, after which the measurement continued. For the other experiments, fully supplemented medium (EBM2 plus 5% FBS and growth factors) was used in E-plate 16. The final data were presented as a plot of time versus normalized cell index (normalized to data at a time point of interest). Wound-healing migration assay. HDLEC migration was measured in a wound-healing assay, which used ibidi Culture-Inserts (ibidi) to generate the wound. An ibidi Culture-Insert has dimensions of 9 mm × 9 mm × 5 mm (width × length × height) and is composed of two wells. One or two inserts were placed into one well of a six-well plate. After being coated with 0.1% gelatin, both wells of inserts were loaded with 100 μ l cell suspension. When cells became fully confluent after attachment, Culture-Inserts were carefully removed by sterile tweezers to start cell migration. For studying the effect of HK2 siRNA on FGF2-stimulated migration (FGF2 was ordered from R&D Systems) and the effect of FGFR1 siRNA and/or FGFR3 siRNA on cell migration, the wound-healing process was monitored for approximately 12 h. To assess the rescue effect of HK2 overexpression in FGFR1 siRNA-treated cells, cell migration was evaluated for approximately 17 h. A Nikon ELIPSE TS100 microscope with a PixeLINK camera was used to image cells at the first time point (T 0 ) and the last time point (T end point ). For data analysis, ImageJ was used to measure the wound area at T 0 and T end point . Migration area was obtained by subtracting area at T end point from area at T 0 . Three-dimensional bead sprouting assay. HDLECs were trypsinized and mixed with collagen-coated Cytodex microcarrier beads (Sigma) in a ratio of 2,500 beads to 1 × 10 6 cells in warm EGM-2 medium in a 15-ml falcon tube. The mixture was incubated at 37 °C for 4 h, with shaking every 20 min to ensure even coating of the beads. After 4 h, the coated beads were transferred to a six-well plate in 2 ml of EGM-2 medium per well and incubated at 37 °C overnight. The next day, coated beads were embedded into a fibrinogen gel. For each well of a 24-well plate, 300 μ l of 3 mg ml −1 fibrinogen in PBS was used, along with 100 μ g ml −1 of aprotinin (Sigma) and 1.5 units per millilitre of thrombin (Sigma). Approximately 250 coated beads were embedded in each well. The plate was then incubated at 37 °C for 1 h to generate a clot. After the gel solidified, human lung fibroblasts in EGM-2 medium were seeded on top at a concentration of 20,000 cells per well. The medium was changed every other day (full EGM-2 medium with 200 ng ml −1 of FGF2), and the plates were imaged on day 6 using a spinning disk confocal microscope (Perkin Elmer). ImageJ was used to measure the sprout length for the data analysis. Adenovirus. Adenovirus encoding green fluorescent protein (GFP), empty CMV vector, HK2 (ref. 31) or MYC (from Vector Biolabs) for in vitro experiments was amplified in 293A cells according to the user manual of the ViraPower Adenoviral Expression System (Life Technologies). Virus was titred using an Adeno-X Rapid Titer Kit (Clontech Laboratories). Analysis of lymphatic development. To induce Cre activity during embryonic stages, each pregnant mouse was injected intraperitoneally with 2 mg tamoxifen (Sigma, T5648) for 2 consecutive days (E10.5-E11.5, E11.5-E12.5 or E12.5-E13.5). Skin tissues were collected at E15.5. Standard whole-mount immunohistochemistry procedure was performed to stain the skin with antibodies against PECAM1 (BD Pharmigen, 553370), VEGFR3 (R&D Systems, AF743), PROX1 (Angiobio, 11-002), Cx40 (ALPHA DIAGNOSTIC, CX40-A), EGFP (Life Technologies, A-11122; Abcam, ab13970) and Alexa fluorescent secondary antibodies (Life Technologies). A spinning disk confocal microscope (Perkin Elmer) and a Leica SP5 confocal microscope were used to generate high-resolution images of immunostained samples. Stitch imaging mode was chosen to image samples of large size. ImageJ was used to crop a representative area from large, stitched images for exhibition. For quantification of lymphatic development in the anterior dorsal skin, comparable regions (on the basis of the blood vessel pattern) between different samples were selected and cropped out of those stitched images as regions of interest for further analysis. Lymphatic development parameters, for example, branching points and LEC nucleus numbers were measured using ImageJ with the 'Lymphatic Vessel Analysis' plugin. If a considerably large area within a region of interest was destroyed during skin dissection, that sample was excluded for analysis. Retinal vasculature analysis. Gene deletion was induced by intragastric injections to pups with 50 μ g tamoxifen (1 mg ml −1 ) at P0, P1 and P2. Mice were euthanized at P5 for analysis of retinal vasculature as previously described 32 . The retinas were incubated with isolectin B4 (IB4) and the following antibodies: anti-collagen IV (Millipore, AB769), anti-Erg1/2/3 (Santa Cruz, SC353), anti-phospho-Histone H3 (PH3, Millipore, 06-570). Retinas were imaged using a Nikon 80i fluorescence microscope and a Leica SP5 confocal microscope with a Leica spectral detection system (Leica 15 SP detector) and Leica application suite advanced fluorescence (LAS-AF) software. Quantification of retinal vascular development and immunostaining were done using Biologic CMM Analyser Software and ImageJ. Analysis of cell cycle distribution. Dorsal skin explants were collected from E15.5 mouse embryos, and minced into ice-cold Dulbecco's Modified Eagle's Medium supplemented with 20% fetal bovine serum and 1.25 mg ml −1 collagenase. Samples were incubated for 30 min at 37 °C, and mechanically dissociated by repeated pipetting until a single cell suspension was achieved. Samples were then centrifuged for 1 min at 2,000g at 4 °C, and cell pellet was resuspended in PBS supplemented with 10% FBS, 5.5 mM glucose and 20 mM HEPES. Cells were incubated in the presence of Hoechst 33342 (25 μ g ml ) as well as the fluorescently conjugated antibodies PECAM1-FITC (BD Pharmingen, 553372) and LYVE1-Alexa647 (eBioscience, 50-0443-82). Samples were washed and resuspended in 0.5 ml PBS on ice for subsequent analysis. BECs and LECs were identified by flow cytometry as PECAM1 +
LYVE1
− and PECAM1 + LYVE1 + events respectively, and, for each population, cell cycle distribution was determined by relative DNA (Hoechst) and RNA (Pyronin Y) content.
Fluorescence-activated cell sorting (FACS) to sort LECs for qPCR analysis. Dorsal skin explants were collected from E15.5 mouse embryos in ice-cold Dulbecco's Modified Eagle's Medium supplemented with 20% fetal bovine serum and 1 mg ml −1 collagenase. Samples were incubated for 1 h at 37 °C, and mechanically dissociated by repeated pipetting until a single-cell suspension was achieved. Samples were then centrifuged for 1 min at 2,000g at 4 °C, and the cell pellet was resuspended in Hank's Buffered Saline Solution supplemented with 10% FBS, 5.5 mM glucose and 20 mM HEPES. Cells were incubated in the presence of the fluorescently conjugated antibodies PECAM1-FITC (BD Pharmingen, 553372), CD45-PECy7 (eBioscience, 25-0451-82) and LYVE1-Alexa647 (eBioscience, 50-0443-82) for 30 min at 37 °C. Samples were pelleted for 1 min at 2,000g at 4 °C, resuspended in 0.5 ml PBS on ice, and filtered through a 35 μ m nylon mesh before flow cytometry analysis and cell sorting. BECs were identified by FACS as PECAM1 
+ events and cells from each population were sorted into RLT lysis buffer (Qiagen) for mRNA preparation (RNeasy Micro kit), cDNA library construction and subsequent qPCR analysis. When analysing qPCR results, wells with a sample melting curve peak at the incorrect temperature were excluded. Corneal lymphangiogenesis model. Slow-releasing pellets containing FGF2 were made as previously described 33 . Surgery to implant the pellets into the mouse cornea was performed as reported 13 . Adult Prox1-CreER T2(KI) ;Hk2 flox/flox and control female mice were injected intraperitoneally with tamoxifen (150 μ g per g body weight) every other day (seven injections in total) before the corneal surgery. One week after the pellet implantation, eyeballs were collected for cornea dissection and immunostaining with LYVE1 (Angiobio, 11-034) and PECAM1 (BD Pharmigen, 553370) antibodies and then used for imaging (spinning disk confocal microscopy) and quantification analysis (ImageJ). Mouse orthotopic pancreatic tumour model. The mouse pancreatic tumour cell line Panc02 was obtained from B. Wiedenmann. One million tumour cells were injected sub-capsularly in the head region of the pancreas of anaesthetized female C57BL/6 mice (7-9 weeks old, Charles River, France) using a 30-gauge needle. At day 3 after tumour inoculation, tumour-bearing mice were treated daily with SSR (30 mg per kg per day) or vehicle (0.6% methylcellulose) by oral gavage. At day 9, primary tumours were removed, weighed and tumour volumes (V) were calculated using the formula V = 0.52 × (a 2 × b), where a represents the smallest tumour diameter and b represents the largest tumour diameter. The incidences of tumour invasion into adjacent organs, haemorrhagic ascites, and regional coeliac and mesenteric lymph node metastases were recorded, and confirmed by immunohistochemistry on paraffin sections. Paraffin-embedded 7-μ m sections were prepared and used for immunohistochemistry using the following antibodies: anti-LYVE1 (Upstate-Cell Signaling Solutions, Bio-connect, Huissen, The Netherlands) and anti-VEGFR3 (eBiosciences). The lymph vessel area in the peri-tumoural area was analysed using KS300 software (Zeiss). The maximum tumour size (for orthotopic pancreatic tumour model) allowed by the Institutional Animal Care and Use Committee of the Katholieke Universiteit Leuven is 1.7 cm. This limit was not exceeded in any of the experiments. Experiments were discontinued and mice were euthanized if the tumour reached either > 1.7 cm in any linear direction or a total volume of 2,000 mm 3 , if mice were not moving easily and spontaneously, if they were losing ≥ 20% of their body weight or if they were clearly not comforted by the degree of analgesia. Statistical analysis. No statistical analysis was used to predetermine sample size. For the corneal lymphangiogenesis assay, the sample size was estimated on the basis of a previous report 13 . Randomization and blinding were not used in our animal studies. Statistical analysis (statistical significance calculation and F-test) was performed using GraphPad Prism 7. Statistical significance between two groups was determined by two-tailed unpaired t-test (assuming normal distribution), and statistical significance between multiple groups was calculated using one-way ANOVA with post hoc tests. Data represent mean ± s.e.m. Data availability. RNA-seq data are available at the Sequence Read Archive under accession number SRP099111. All other data are available from the corresponding author upon reasonable request. Figure 5 | Proliferation and migration of HDLECs with FGFR1 and/or FGFR3 knockdown. a, Proliferation of HDLECs treated with indicated siRNAs was measured by using xCELLigence (see Methods) (n = 4 wells of samples for each condition; representative of two independent experiments). b, Wound-healing assay to assess the migration of HDLECs transfected with siRNAs as indicated. Red dotted lines outline wound area in the last time-point images of HDLECs with different treatments. c, Wound closure area between the first and last time points was measured and normalized to that of control siRNAtreated HDLECs (n = 8 imaging fields for control siRNA, FGFR1 siRNA and FGFR3 siRNA; n = 7 imaging fields for FGFR1/FGFR3 siRNAs; representative of two independent experiments). Data represent mean ± s.e.m., * * * P < 0.001, calculated by one-way ANOVA plus Tukey's multiple comparisons test (a, c). Figure 7 | Role of HK2 in FGF-dependent cellular behaviours. a, b, Proliferation (a; n = 4 wells of samples for each condition) and migration (b; n = 4 imaging fields for each condition) of HDLECs with indicated siRNAs, which were serum-starved and treated with or without FGF2. c, d, Proliferation (c; n = 4 wells of samples for control siRNA + Ad-control, control siRNA + Ad-HK2 and FGFR1 siRNA + Ad-control; n = 3 wells of samples for FGFR1 siRNA + Ad-HK2) and migration (d; n = 8 imaging fields for each condition) of HDLECs with indicated siRNAs, which were cultured in fully supplemented medium and treated with control or HK2 adenovirus. Proliferation was measured using xCELLigence and migration was analysed through a wound-healing assay (see Methods). Wound closure area between the first time point and the last time point was measured and normalized to that of control siRNA-treated HDLECs (b) or HDLECs treated with control siRNA and control adenovirus (d). Red dotted lines outline wound area in the last time-point images of HDLECs with different treatments. e, f, Representative images and quantification of microcarrier beads coated with HDLECs under treatments as indicated. Total length of LEC sprouts per bead was quantified. e, f, Arrowheads indicate sprouts extending from the beads. For e, n = 14 beads for control siRNA, n = 14 beads for HK2 siRNA, n = 19 beads for control siRNA + FGF2 and n = 25 beads for HK2 siRNA + FGF2. For f, n = 25 beads for each condition. Data represent mean ± s.e.m., * * P < 0.01, * * * P < 0.001, calculated by one-way ANOVA plus Sidak's multiple comparisons test (a-f).
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